Sun Pharmaceutical Industries Limited
NSE: SUNPHARMA BSE: SUNPHARMA
Prev Close
1735.35
Open Price
1740.45
Volume
2,015,490
Today Low / High
1725.3 / 1760.3
52 WK Low / High
1377.2 / 1960.35
Range
1,652 - 1,826
Upper Circuit (5%)
1,826.06
Lower Circuit (5%)
1,652.15
Prev Close
1736.7
Open Price
1739.8
Volume
30,376
Today Low / High
1726 / 1758.9
52 WK Low / High
1376.75 / 1960.2
Range
1,658 - 1,833
Upper Circuit (5%)
1,832.51
Lower Circuit (5%)
1,657.99
The stock performance of Sun Pharmaceutical Industries Limited on both the NSE and BSE. On the NSE, the stock is priced at ₹1739.1 (target range: ₹1,652 - ₹1,826), reflecting a slight increase of 0.22%, with a trading volume of 2,015,490 shares. On the BSE, the stock is trading at ₹1745.25 (target range: ₹1,658 - ₹1,833), up by 0.49% with a volume of 30,376 shares. Both exchanges show similar low and high prices, with NSE at ₹1725.3 - ₹1760.3 and BSE at ₹1726 - ₹1758.9 The 52-week range stands at ₹1960.35 - ₹1377.2 on both exchanges. Both NSE and BSE show positive movement, indicating an upward stock trend—an appealing opportunity for growth-focused investors.
Sun Pharmaceutical Industries Limited Chart Graph
Comprehensive Overview of Sun Pharmaceutical Industries Limited
ISIN
INE044A01036
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
1,922,919
Market Cap
4,172,587,848,000
Last Dividend
13.5
Range
1377.2-1960.35
Official Website
IPO Date
1996-01-01
DCF Diff
256.90
DCF
1,480
Latest Dividend Details for SUNPHARMA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-07-12 | July 12, 24 | 5 | 5 | 2024-07-12 | 2024-08-16 | |
| 2024-02-09 | February 09, 24 | 8.5 | 8.5 | 2024-02-09 | 2024-02-23 | |
| 2023-07-28 | July 28, 23 | 4 | 4 | 2023-07-28 | 2023-09-08 | |
| 2023-02-08 | February 08, 23 | 7.5 | 7.5 | 2023-02-08 | 2023-03-02 | |
| 2022-08-19 | August 19, 22 | 3 | 3 | 2022-08-22 | 2022-09-20 |
Comprehensive Annual Financial Performance Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 47,758.45 Cr | 24,812.11 Cr | 22,946.34 Cr | 0.4805 | 3,127.70 Cr | 3,437.14 Cr | 10,468.18 Cr | 9,576.38 Cr | 39.91 | 13,836.33 Cr | 0.2005 |
| 2023-03-31 | 43,278.87 Cr | 10,662.16 Cr | 32,616.71 Cr | 0.7536 | 2,307.72 Cr | 2,818.46 Cr | 9,304.75 Cr | 8,473.58 Cr | 35.32 | 12,084.93 Cr | 0.1958 |
| 2022-03-31 | 38,426.42 Cr | 11,707.65 Cr | 26,718.77 Cr | 0.6953 | 2,132.51 Cr | 2,186.83 Cr | 8,147.17 Cr | 3,272.73 Cr | 13.64 | 6,699.65 Cr | 0.0852 |
| 2021-03-31 | 33,139.18 Cr | 9,885.42 Cr | 23,253.76 Cr | 0.7017 | 2,102.82 Cr | 2,385.26 Cr | 6,427.62 Cr | 2,903.82 Cr | 12.10 | 4,998.62 Cr | 0.0876 |
| 2020-03-31 | 32,325.17 Cr | 10,471.27 Cr | 21,853.90 Cr | 0.6761 | 1,925.17 Cr | 2,228.21 Cr | 4,947.77 Cr | 3,764.93 Cr | 15.69 | 7,312.90 Cr | 0.1165 |
Essential Financial Ratios Every Investor Must Know
Comprehensive Annual Balance Sheet Overview
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 9,285.65 Cr | 85,462.88 Cr | 18,356.91 Cr | 63,666.7500 Cr | 3,273.67 Cr | -6,011.98 Cr | 10,294.89 Cr | 11,300.05 Cr | 126.54 Cr | 489.37 Cr | 6,441.23 Cr | 16,984.4000 Cr |
| 2023-03-31 | 4,623.73 Cr | 80,743.59 Cr | 21,428.12 Cr | 55,995.3800 Cr | 6,889.66 Cr | 2,265.93 Cr | 10,513.05 Cr | 11,353.73 Cr | 7,256.18 Cr | 343.53 Cr | 5,457.48 Cr | 19,906.3800 Cr |
| 2022-03-31 | 4,508.25 Cr | 69,799.87 Cr | 18,733.76 Cr | 48,011.2200 Cr | 1,290.30 Cr | -3,217.95 Cr | 8,996.81 Cr | 11,168.89 Cr | 11,402.24 Cr | 618.75 Cr | 4,959.21 Cr | 17,200.5500 Cr |
| 2021-03-31 | 6,273.03 Cr | 67,666.73 Cr | 18,186.90 Cr | 46,462.7800 Cr | 3,868.58 Cr | -2,404.45 Cr | 8,997.02 Cr | 11,171.51 Cr | 8,687.82 Cr | 718.55 Cr | 6,482.39 Cr | 16,145.6300 Cr |
| 2020-03-31 | 5,676.61 Cr | 68,252.46 Cr | 19,127.77 Cr | 45,264.4500 Cr | 8,314.88 Cr | 2,638.27 Cr | 7,874.99 Cr | 11,226.34 Cr | 4,904.85 Cr | 759.27 Cr | 5,245.75 Cr | 15,706.4300 Cr |
Annual Financial Cash Flow Statement Overview
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 12,134.9800 Cr | -690.2000 Cr | -6,710.1600 Cr | 9,933.1700 Cr | 4,661.9200 Cr | 9,285.6500 Cr | -2,201.8100 Cr | 9,576.3800 Cr | -3,389.9300 Cr | -2,898.1700 Cr | 598.8100 Cr |
| 2023-03-31 | 4,959.3300 Cr | -7,943.6800 Cr | 2,376.0700 Cr | 2,873.7500 Cr | 115.4800 Cr | 4,623.7300 Cr | -2,085.5800 Cr | 9,408.4300 Cr | 5,129.6600 Cr | -2,518.8800 Cr | -1,202.2000 Cr |
| 2022-03-31 | 8,984.5400 Cr | -5,724.7400 Cr | -5,193.4600 Cr | 7,489.5000 Cr | -1,764.7800 Cr | 4,508.2500 Cr | -1,495.0400 Cr | 4,481.3200 Cr | -2,636.7100 Cr | -2,158.9200 Cr | 306.9500 Cr |
| 2021-03-31 | 6,170.3700 Cr | 536.2200 Cr | -5,980.4800 Cr | 5,000.2400 Cr | 596.4200 Cr | 6,273.0300 Cr | -1,170.1300 Cr | 2,799.3700 Cr | -4,371.8500 Cr | -1,559.4700 Cr | -1,080.2900 Cr |
| 2020-03-31 | 6,554.7700 Cr | -2,588.8400 Cr | -5,715.1400 Cr | 5,012.7700 Cr | -1,385.6900 Cr | 5,676.6100 Cr | -1,542.0000 Cr | 5,009.5900 Cr | -3,122.9900 Cr | -1,662.6400 Cr | 256.7700 Cr |
Quarterly Financial Performance Highlights
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 13,291.39 Cr | 5,797.81 Cr | 7,493.58 Cr | 0.5638 | 3,184.96 Cr | 3,040.16 Cr | 12.70 | 4,292.96 Cr | 0.2287 |
| 2024-06-30 | 12,652.75 Cr | 5,785.18 Cr | 6,867.57 Cr | 0.5428 | 3,002.94 Cr | 2,835.62 Cr | 11.82 | 4,140.17 Cr | 0.2241 |
| 2024-03-31 | 11,982.90 Cr | 5,330.11 Cr | 6,652.79 Cr | 0.5552 | 2,441.17 Cr | 2,654.58 Cr | 11.10 | 3,539.45 Cr | 0.2215 |
| 2023-12-31 | 12,156.86 Cr | 2,736.94 Cr | 9,419.92 Cr | 0.7749 | 3,104.89 Cr | 2,523.75 Cr | 10.52 | 3,657.22 Cr | 0.2076 |
| 2023-09-30 | 12,003.11 Cr | 2,787.09 Cr | 9,216.02 Cr | 0.7678 | 2,840.17 Cr | 2,375.51 Cr | 9.90 | 3,472.99 Cr | 0.1979 |
Comprehensive Quarterly Financial Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 8,012.54 Cr | 12,742.83 Cr | 20,755.37 Cr | 0.00 Cr | 9,935.65 Cr | 46,105.45 Cr | 11,248.33 Cr | 88,115.66 Cr | 18,736.01 Cr |
| 2024-06-30 | -19,090.06 Cr | 38,180.12 Cr | 19,090.06 Cr | 0.00 Cr | 0.00 Cr | 19,090.06 Cr | 0.00 Cr | 0.00 Cr | -67,105.97 Cr |
| 2024-03-31 | 10,520.68 Cr | 8,584.54 Cr | 19,105.22 Cr | 11,260.24 Cr | 9,868.29 Cr | 43,433.11 Cr | 11,300.05 Cr | 85,462.88 Cr | 18,356.91 Cr |
| 2023-12-31 | -14,833.25 Cr | 29,666.50 Cr | 14,833.25 Cr | 0.00 Cr | 0.00 Cr | 14,833.25 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 5,403.10 Cr | 10,364.24 Cr | 15,767.34 Cr | 11,302.65 Cr | 9,956.41 Cr | 39,353.80 Cr | 11,118.54 Cr | 79,441.16 Cr | 16,244.28 Cr |
Quarterly Cash Flow Statement: A Detailed Financial Overview
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 2,835.62 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 2,654.58 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 2,523.75 Cr | 1,244.28 Cr | 0.00 Cr | 0.00 Cr | 1,244.28 Cr | 8,466.29 Cr | 7,222.01 Cr | 0.00 Cr | 1,244.28 Cr |
| 2023-09-30 | 2,375.51 Cr | 1,265.64 Cr | 0.00 Cr | 0.00 Cr | 1,265.64 Cr | 7,222.01 Cr | 5,956.37 Cr | 0.00 Cr | 1,265.64 Cr |
| 2023-06-30 | 2,022.54 Cr | 1,302.64 Cr | 0.00 Cr | 0.00 Cr | 1,302.64 Cr | 5,939.26 Cr | 4,636.62 Cr | 0.00 Cr | 1,302.64 Cr |
Historical Stock Splits Overview
| Date | Label | Split Ratio |
|---|---|---|
| 2013-07-29 | July 29, 13 | 2:1 |
| 2010-11-25 | November 25, 10 | 5:1 |
| 2004-05-27 | May 27, 04 | 2:1 |
| 2003-01-13 | January 13, 03 | 2:1 |
| 2000-03-08 | March 08, 00 | 3:1 |
Executive Profiles
Gender: male
Year Born: 1984
Gender: male
Year Born: 1954
Gender: male
Year Born:
Gender: male
Year Born: 1967
Gender: male
Year Born: 1963
Gender: male
Year Born: 1955
Gender: male
Year Born:
Gender: Not Specified
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1971
Frequently Asked Questions about Sun Pharmaceutical Industries Limited
The CEO of the company is Mr. Dilip Shantilal Shanghvi.
The current trading price of the stock is ₹1,739.10.
The 52-week price range of this stock is ₹1377.2-1960.35.
The market capitalization of the company is ₹417,258.78 crores.
The dividend yield represents the percentage of a company stock price paid out as dividends annually. For example, if the dividend yield is 0.78%, it means the company pays this percentage of its stock price as a dividend each year.
The P/E ratio is a measure of a company stock price relative to its earnings per share (EPS). For this stock, the current P/E ratio is 37.66.
The company operates in the Healthcare sector.
The current price of Sun Pharmaceutical Industries Limited is ₹1,739.10. If the stock takes a bullish turn, you can expect the target price to be around ₹1,826.06. On the other hand, if the market turns bearish, the target price could drop to approximately ₹1,652.15.
The company, Sun Pharmaceutical Industries Limited (ISIN: INE044A01036), is a leading player in the Drug Manufacturers - Specialty & Generic sector in India. With a market capitalization of ₹417,258.78 crores and an average daily trading volume of 1,922,919 shares, it is actively engaged in the Drug Manufacturers - Specialty & Generic industry. The company recently declared a dividend of 13.5."